

Amendments to the Drawings:

The attached drawing sheets include changes to Figs. 2B and 2C and a new Fig. 2D. Fig. 2B has been changed to make the drawing lines clearer. Fig 2C has been changed to remove the nasal occlusion device represented as an external U-shaped clamp 29F. Fig. 2D has been added to show the leak resistant interface of an oral interface and nasal occlusion device depicted together in use in one figure. Fig. 19 has been changed to add reference character 224 and to correct the line for reference character 220 to point to the mask rather than the tube.

REMARKS/ARGUMENTS

In the specification, paragraphs 001, 017, 031, 033, 034, and 068 have been amended to correct minor editorial problems or to correspond to the figures. Specifically, paragraph 001 has been amended to include the patent number of the priority application. Paragraphs 017, 033, and 034 have been amended to make reference to new Fig. 2D. Paragraph 031 has been amended to properly refer to the patient interface 64 rather than an exit. Paragraph 068 has been amended to correct typographical errors.

In the drawings, Fig. 2B has been changed to make the drawing lines clearer. Fig 2C has been changed to remove the nasal occlusion device represented as an external U-shaped clamp 29F. Fig. 2D has been added to show the leak resistant interface of an oral interface and nasal occlusion device depicted together in use in one figure. Applicant submits that the new Fig. 2D does not add new matter. Fig. 19 has been changed to add reference character 224 to refer to the computer 224 and to correct the line for reference character 220 to point to the mask rather than the tube.

Applicant attaches an information disclosure statement on form PTO 1149 listing references from application 09/498,504 so that such references may be listed on any patent that may result from the instant application. Applicant also attaches a terminal disclaimer in compliance with 37 CFR 1.321(c) to overcome the rejection for double patenting, along with PTO-2038 enclosing the required fees for the late information disclosure statement (\$180) and the terminal disclaimer (\$65) for a total of \$245. **The Director is hereby authorized to charge any additional fee(s) or underpayments of fee(s) under 37 CFR 1.16 and 1.17 or credit any overpayments to Deposit Account 12-0434.**

Applicant respectfully requests allowance of the application.

Respectfully submitted and signed on May 6/05.

Anthony R. Lambert
ANTHONY R. LAMBERT
Registration No. 32,813
Customer no. 020212
Telephone: (780) 448-7326
AGENT OF RECORD